Jan A. Burger, MD, PhD

home / authors / jan-a-burger-md-phd

Articles

Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLL

March 1st 2022

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Burger on the Changing Treatment Landscape of CLL

Jan A. Burger, MD, PhD

February 17th 2022

Jan A. Burger, MD, PhD, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Dr. Burger on the Benefits of Novel Combination Approaches in CLL

Jan A. Burger, MD, PhD

January 13th 2022

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

Dr. Burger on Choosing Frontline Therapy in CLL

Jan A. Burger, MD, PhD

January 5th 2022

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

Dr. Jan A. Burger on Role of MRD-Negativity in CLL

Jan A. Burger, MD, PhD

October 15th 2016

Jan A. Burger, MD, PhD, associate professor, department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD)-negativity in chronic lymphocytic leukemia (CLL).